Clinical Trial Finder

Inclusion Criteria:

• - 1.

Ability to provide and document informed consent and willing and able to comply with all study procedures.

• - Participants diagnosed with advanced solid tumors including but not limited to metastatic castration-resistant prostate cancer, melanoma, pancreatic cancer, hepatocellular carcinoma, ovarian cancer and renal cell carcinoma.

• - Participants have received approved therapies according to their diagnosis.

• - Participants must have an available tumor tissue sample.

A fresh tumor biopsy may be performed if no archival sample is available.

• - Eastern Cooperative Oncology Group performance status of less than or equal to 2.

• - Life expectancy of at least 12 weeks.

• - Evidence of measurable tumor for evaluation.

• - Acceptable end organ function according to laboratory results.

• - Patients must agree to use highly-effective contraception during the study, and not donate sperm or ova.

Exclusion Criteria:

• - Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.

• - Another malignancy that required treatment within the past 2 years.

Participants who have had curative therapy for non-melanomatous skin cancer, localized prostate cancer (Gleason score < 6), or carcinoma in situ are eligible for the study.

• - Active viral, bacterial, or fungal infection requiring systemic treatment within 1 week of initiation of study drug.

Participants are eligible after SARS CoV 2-related symptoms have fully recovered for ≥ 72 hours.

• - History of immunodeficiency.

Participants with HIV are eligible if they have a CD4+ count ≥ 300/µL, undetectable viral load, and maintained on antiretroviral therapy for a minimum of 4 weeks.

• - Prior autologous/allogeneic stem cell or tissue/solid organ transplant.

• - Prior treatment with MGD009, enoblituzumab, or other B7-H3 targeted agents for cancer.

• - Clinically significant cardiovascular disease, lung compromise, venous insufficiency, or gastrointestinal disorders.

• - Participants with greater than Grade 1 peripheral neuropathy.

• - Participants who have a history of severe adverse events (AEs) from immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or CTLA-4 inhibitors).

All other AEs from prior immune checkpoint inhibitors must be resolved to Grade 1 or less. Participants with any grade neurologic toxicity from prior immune checkpoint inhibitors are excluded.

• - Pleural effusion or ascites.

Trace pleural or peritoneal fluid is not exclusionary.

• - History of Guillain-Barre syndrome, myasthenia gravis, or other autoimmune sensory or motor neuropathies.

Arms

Experimental: Cohort -1

vobramitamab duocarmazine at dose level -1 and lorigerlimab intravenously (IV) every 4 weeks

Experimental: Cohort 1

vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks

Experimental: Cohort 2

vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks

Experimental: Cohort 3

vobramitamab duocarmazine at dose level 2 and lorigerlimab IV every 4 weeks

Experimental: Cohort 4

vobramitamab duocarmazine at dose level 3 and lorigerlimab IV every 4 weeks

Experimental: Cohort 5

vobramitamab duocarmazine at dose level 4 and lorigerlimab IV every 4 weeks

Experimental: Cohort Expansion

maximum tolerated dose of vobramitamab duocarmazine and lorigerlimab IV every 4 weeks

Interventions

Biological: - vobramitamab duocarmazine

Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.

Biological: - lorigerlimab

Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.